Home › Healing & Recovery › BPC-157
HealingResearch chemical

BPC-157

Also known as: Body Protection Compound 157

A synthetic peptide fragment that has become one of the most studied “healing” peptides in animal research, though it has not completed human clinical trials.

Researched & fact-checked by the Peptide Almanac Editorial Team · Last updated

6 cited sources Research chemical — not approved No dosing advice How we research & review →

Quick facts

Class
Synthetic pentadecapeptide (15 amino acids)
Derived from
A partial sequence of human gastric protein BPC
Studied for
Tendon, ligament, muscle & gut healing (animal models)
Evidence level
Extensive preclinical; no completed human trials
Approval
Not FDA-approved for any use
Sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Half-life
Short (minutes) in blood in animal studies
Routes studied
Oral, intraperitoneal, intramuscular (animals)
Anti-doping
Prohibited by WADA
Educational summary only — not medical advice. BPC-157 is not an approved medicine for general use. Evidence is limited and does not establish human safety or efficacy.

Key takeaways

  • BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice.
  • Nearly all evidence is from animal studies — there are no completed, published human clinical trials.
  • The strongest research signals are tendon/ligament/muscle healing and protection of the stomach and gut lining.
  • Proposed mechanisms center on promoting new blood-vessel growth (VEGF) and the nitric-oxide system.
  • It is not FDA-approved, the FDA has restricted its compounding, and it is banned in sport by WADA.

Overview

BPC-157 ("Body Protection Compound 157") is a synthetic peptide of 15 amino acids, corresponding to a partial sequence of a larger protective protein discovered in human gastric juice. The idea behind it is simple and appealing: the stomach heals constantly in a harsh, acidic environment, so a protein fragment that helps drive that protection might accelerate repair elsewhere too.

Over roughly three decades, a research group led by Predrag Sikirić in Croatia — and, more recently, a growing number of independent laboratories — has published a large body of animal work suggesting BPC-157 speeds the healing of many tissue types. In fitness, biohacking, and "regenerative" circles it is marketed as a recovery peptide, often nicknamed the "Wolverine peptide."

The single most important thing to understand is the gap between popularity and proof: despite the volume of preclinical papers, there are no completed, peer-reviewed human clinical trials demonstrating that BPC-157 is safe and effective in people. Everything below should be read with that caveat.

How it works

BPC-157's proposed mechanisms come from animal and cell studies and are still being characterized. Several recurring themes appear in the literature:

Angiogenesis (new blood vessels)

BPC-157 appears to upregulate vascular endothelial growth factor receptor 2 (VEGFR2) signaling and promote the formation of new blood vessels at injury sites. Better blood supply means more oxygen and nutrients reaching damaged tissue, a plausible basis for faster repair.[1]

The nitric oxide (NO) system

Multiple studies suggest BPC-157 interacts with the nitric-oxide pathway, which governs blood flow, blood pressure, and tissue protection. This may explain reported effects on both healing and the cardiovascular system.[3]

Growth-factor and cell-migration effects

In tendon-cell experiments, BPC-157 increased the survival, migration, and outgrowth of the cells responsible for rebuilding tendon — a direct cellular rationale for its tendon-healing claims.

Research & benefits

Tendon, ligament & muscle healing

These are the most cited claims. In rodent models of transected (surgically cut) Achilles tendon, crushed muscle, and damaged ligament, BPC-157 accelerated functional recovery and improved healing markers versus untreated controls.[2] A 2019 review pulled this musculoskeletal soft-tissue literature together. Crucially, none of this has been reproduced in controlled human trials.

Gastrointestinal protection

This is the original and arguably strongest preclinical signal, consistent with the peptide's gastric origin. In numerous rodent studies BPC-157 protected against and helped heal stomach and intestinal lesions, including damage caused by NSAIDs (like ibuprofen) and alcohol.[1]

Nerve, brain & other tissues

Smaller bodies of animal work have explored BPC-157 in nerve-crush injury, traumatic brain injury models, wound healing, and counteracting side effects of certain drugs.[3]

Reality check: Promising animal results frequently fail to translate to humans — most drugs that work in rodents never make it through human trials. The complete absence of completed human trials is the defining limitation of the BPC-157 evidence base.

Safety & side effects

In animal studies, BPC-157 has shown a notably clean short-term safety profile, with few reported adverse effects even at high doses. That is reassuring but limited — animals are not people, and short-term is not long-term. Specific concerns for humans include:

  • No long-term human safety data. There are simply no published long-term human studies.
  • Source and purity risk. Products sold as "research chemicals" are unregulated; what is actually in the vial — purity, sterility, even whether it contains BPC-157 at all — is not guaranteed.
  • Theoretical angiogenesis concern. Because BPC-157 promotes new blood-vessel growth, there is a theoretical (unproven) worry about its effect on existing tumors, which also depend on blood supply. This warrants caution and professional input.

BPC-157 is not approved by the FDA for any human use and is not a licensed medicine in the US, UK, EU, or most jurisdictions. In the US it was widely sold as a "research chemical," but in 2023 the FDA placed it in a category that effectively bars it from pharmacy compounding. It is prohibited in competitive sport by the World Anti-Doping Agency. Laws differ by country and change over time — verify current local regulations yourself. This page is not legal advice.

BPC-157 vs TB-500

The two peptides most associated with "healing" are often discussed — and sometimes used — together. They are different molecules with different origins.

BPC-157TB-500
OriginFragment of a human gastric proteinSynthetic fragment of Thymosin Beta-4
Primary research focusTendon/gut healing, cytoprotectionCell migration, flexibility, broad tissue repair
Proposed mechanismVEGF/angiogenesis, nitric-oxide systemActin regulation, cell migration
Human evidenceNone completedLimited (Tβ4 itself studied in trials)
Approval / WADANot approved · WADA-bannedNot approved · WADA-banned

Frequently asked questions

Is BPC-157 FDA approved?

No. BPC-157 is not approved for any medical use, and in 2023 the FDA restricted its use in pharmacy compounding.

Does BPC-157 actually work for tendon and joint healing?

It is unproven in humans. The tendon-healing results come from rodent studies; no completed human clinical trial has confirmed them, so its real-world effectiveness is unknown.

Is BPC-157 taken orally or by injection?

Both routes have been used in animal studies, and it is unusually stable in gastric juice in the lab. But because there are no human dosing trials, there is no established route or dose for people — we deliberately do not publish a protocol.

Is BPC-157 legal?

It is often sold "for research purposes," but it is not a legal medicine and its regulatory status is restrictive and changing. It is also banned in sport. See our disclaimer.

Is BPC-157 safe?

Animal studies show few short-term side effects, but there is no long-term human safety data, and unregulated products carry purity and sterility risks. Always consult a qualified clinician.

What's the difference between BPC-157 and TB-500?

They are different molecules: BPC-157 comes from a gastric protein and is studied mostly for tendon and gut healing, while TB-500 is a Thymosin Beta-4 fragment studied for cell migration and broad tissue repair. Neither is approved.

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

  1. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. Peer-reviewed study
  2. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010. Peer-reviewed study
  3. Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-eNOS pathway. Sci Rep. 2020. Peer-reviewed study
  4. Józwiak M, Bauer M, Kamysz W, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025. Peer-reviewed study
  5. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019. Peer-reviewed study
  6. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. Peer-reviewed study
Compare BPC-157: BPC-157 vs TB-500 · BPC-157 vs GHK-Cu
Related guides: TB-500 · GHK-Cu · LL-37 · All Healing & Recovery peptides →

Educational content only — not medical advice. See our Privacy Policy.